Home › Conditions › Hospital-Acquired Pneumonia (HAP)
Respiratory
Hospital-Acquired Pneumonia (HAP)
Pneumonia developing 48 hours or more after admission, or in someone discharged within the last 7–10 days. It is not CAP that happened to be diagnosed on a ward — the organisms differ, the resistance risk differs, and so does the antibiotic. Ventilator-associated pneumonia is excluded from this definition and is an ICU problem. The decision that matters is whether they are at higher risk of resistance, because that, not severity alone, drives whether they need IV broad-spectrum cover.
NICE NG250 — Pneumonia
The pathway
Is it actually HAP?
- 48 hours or more after admission, not incubating on arrival
- Or presenting having been discharged in the last 7–10 days
- Under 48 hours: treat as community-acquired, whatever ward they are on
- VAP is excluded from this definition — that is an ICU problem
Rule out the ward mimics first: aspiration · pulmonary oedema after days of IV fluids · atelectasis post-op · PE · drug reaction.
Assess and investigate
- NEWS2. If septic, run the sepsis pathway alongside
- CXR
- Send a respiratory sample — sputum, nasopharyngeal swab or tracheal aspirate. Routine in HAP, unlike CAP
- FBC, CRP, U&E, LFTs, gas. Blood cultures if septic
There is no validated severity score for HAP. Severity is clinical judgement — CURB-65 is for CAP and will mislead you here.
Higher risk of resistance? This is the decision
- Onset more than 5 days after admission
- Severe lung disease or immunosuppression
- Recent broad-spectrum antibiotics
- Known MDR colonisation
- Recent health or social care contact before this admission
Onset day 3–5 with none of these can follow the community-acquired choices. Weigh the C. difficile risk of broad-spectrum cover — that is why this is not automatic.
Antibiotics — within 4 hours
- Non-severe, no resistance risk: co-amoxiclav 500/125mg TDS, 5 days then review. Allergy: doxycycline, cefalexin or co-trimoxazole
- Severe or higher resistance risk (IV, on microbiology advice): piperacillin-tazobactam 4.5g TDS · ceftazidime 2g TDS · ceftriaxone 2g OD · cefuroxime 750mg TDS · meropenem 0.5–1g TDS
- MRSA suspected or confirmed: add vancomycin or teicoplanin. Linezolid only on specialist advice
- Levofloxacin only if nothing else is suitable — MHRA Jan 2024
Local antimicrobial policy outranks every drug named here.
Review at 5 days
- Review at 5 days and consider stopping if clinically stable
- IV to oral by 48 hours where severity allows
- Narrow the antibiotic when the sample result lands — that is why you sent it
- CRP or procalcitonin at day 3–4 if worried about failure
- Not improving, or MDR organism: microbiology advice, not empirical escalation
Prevent the next one
- Sit them up — 30–45° unless contraindicated
- Swallow assessment after stroke, or with a wet voice or cough on drinking
- Mouth care
- Mobilise, and involve physiotherapy early after surgery
- Review the PPI — acid suppression is a risk factor and many inpatient PPIs have no indication
- Deprescribe sedatives where you can
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Co-amoxiclav | 500/125mg TDS, 5 days then review | PO | Non-severe HAP not at higher risk of resistance. |
| Piperacillin-tazobactam | 4.5g TDS (QDS if severe) | IV | Severe, or higher resistance risk. One option among several — local policy and microbiology advice decide. |
| Ceftriaxone | 2g OD | IV | Alternative IV first-line. Per local policy. |
| Meropenem | 0.5–1g TDS | IV | Reserve. Specialist microbiological advice, usually for known or likely resistant organisms. |
| Vancomycin | 15–20mg/kg BD–TDS, level-adjusted | IV | Added to an IV first-line agent for suspected or confirmed MRSA. Loading dose 25–30mg/kg if seriously ill; max 2g per dose. Monitor levels. |
| Doxycycline | 200mg day 1, then 100mg OD (5 days) | PO | Oral alternative in penicillin allergy, non-severe, low resistance risk. |
When to escalate
- Septic — run the sepsis pathway alongside this, NEWS2 sets the antibiotic clock
- Severe, or higher risk of resistance — IV antibiotics on specialist microbiological advice
- Not improving at 5 days, or a multidrug-resistant organism — microbiology, not empirical escalation
- Rising oxygen requirement or type 1 failure — critical care review; consider HFNO
- Suspected empyema or parapneumonic effusion — ultrasound and respiratory referral
Reference: NICE NG250 Pneumonia: diagnosis and management (2025, replaced NG138 and NG139) — hospital-acquired pneumonia sections 1.5, 1.7 and 1.11
Practise and explore
Practise a case or explore differentials here on the website. The optional browser app adds personal learning tools and saved progress.